April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Topical Delivery Of Dexamethasone Mixed Nanomicellar Formulation To The Posterior Segment: Formulation Development, Optimization And In Vivo Ocular Tissue Distribution
Author Affiliations & Notes
  • Kishore CHOLKAR
    Pharmaceutical Sciences, University of Missouri Kansas City, Kansas City, Missouri
  • Sudharshan Hariharan
    Pharmaceutical Sciences, University of Missouri Kansas City, Kansas City, Missouri
  • Rajyalakshmi Earla
    Pharmaceutical Sciences, University of Missouri Kansas City, Kansas City, Missouri
  • Sriram Gunda
    Pharmaceutical Sciences, University of Missouri Kansas City, Kansas City, Missouri
  • Ashim K. Mitra
    Pharmaceutical Sciences, University of Missouri Kansas City, Kansas City, Missouri
  • Footnotes
    Commercial Relationships  Kishore Cholkar, None; Sudharshan Hariharan, None; Rajyalakshmi Earla, None; Sriram Gunda, None; Ashim K. Mitra, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3214. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kishore CHOLKAR, Sudharshan Hariharan, Rajyalakshmi Earla, Sriram Gunda, Ashim K. Mitra; Topical Delivery Of Dexamethasone Mixed Nanomicellar Formulation To The Posterior Segment: Formulation Development, Optimization And In Vivo Ocular Tissue Distribution. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3214.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The objective of this study was to develop a stable mixed nanomicellar formulation, optimization and characterization. Also, determine the ocular tissue distribution upon topical drop administration in Male New Zealand albino rabbits.

Methods: : Vitamin E TPGS and octoxynol-40, USFDA approved non-ionic surfactants, are used in different ratios to obtain an optimized formulation. Dexamethasone is a steroid, hydrophobic drug. It is the drug of choice for the treatment of posterior uveitis. Its solubility was improved with the development of this novel mixed nanomicelle formulation to get an overall concentration of 1 mg/mL. The novel mixed nanomicelle formulation was prepared by solvent evaporation technique. The optimized formulation was characterized for its improvement in drug solubulization efficiency, osmolality and micelle stability. Drug ocular bioavailability studies/tissue distribution studies were conducted in male New Zealand rabbits by topical drop administration. Liquid-liquid extraction was used for the extraction of dexamethasone from the homogenized tissues. Extracted drug analyzed using LC-MS/MS.

Results: : The optimized formulation showed a effective micelle size of about 18 nm with encapsulation ratio percentage > 95%. Drug entrapment was confirmed by NMR spectroscopy, the clarity of the formulation was determined by UV spectroscopy, thermal stability and regeneration time of obtimized mixed nanomicelle formulation was found to be above point of detection (90° C). Long term storage and stability studies of the formulation at 40° C, room temperature and at 4° C showed improved stability. Therapeutical drug concentrations, 50 ng/gm tissue, were observed in retina-choroid.

Conclusions: : A clear mixed nanomicelle formulation was prepared and optimized. The novel mixed nano micellar formulation had shown increase in the drug solubility with good entrapment. The smaller size, lower poly dispersity index and improved stability of the formulation were observed. The formulation has shown improved stability for a longer period of time. Therapeutic levels of drug were observed in the posterior segment of eye (retina-choroid) after topical administration.

Keywords: retina • choroid • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×